A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)

Trial Profile

A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs CM 4612 (Primary)
  • Indications Autistic disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms Blum Study
  • Sponsors Curemark
  • Most Recent Events

    • 18 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 23 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top